Skip to main content
. 2024 Nov 20;15:1461571. doi: 10.3389/fphar.2024.1461571

FIGURE 6.

FIGURE 6

The cost-effectiveness acceptability curve in China (A) Patients with ITT, (B) Patients with TAP ≥ 5%.